Review Article

Functional Polymorphisms in COX-2 Gene Are Correlated with the Risk of Oral Cancer

Dong Li,1 Shu-Hong Hao,2 Yan Sun,2 Chun-Mei Hu,2 Zhi-Hua Ma,1 Zhi Ming Wang,3 Jie Liu,4 Hong Bo Liu,5 Ming Ye,5 Yu Fei Zhang,3 Dong Sheng Yang,3 and Guang Shi2

1Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun 130041, China
2The Department of Hematology and Oncology, The Second Hospital of Jilin University, Changchun 130041, China
3Department of Oral Surgery, Shengjing Hospital of Youyi Medical University, Jilong 999077, Hong Kong
4Experimental Technology Center of Youyi Medical University, Jilong 999077, Hong Kong
5Department of Statistics, School of Public Health, Youyi Medical University, Jilong 999077, Hong Kong

Correspondence should be addressed to Guang Shi; sgtt1980@qq.com

Received 19 December 2014; Revised 1 March 2015; Accepted 2 March 2015

Academic Editor: Paul W. Doetsch

Copyright © 2015 Dong Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. This meta-analysis investigated the association between functional COX-2 gene polymorphisms and the risk of oral cancer. Methods. Several electronic databases were searched for published studies using combinations of keywords related to COX-2 gene polymorphisms and oral cancer. After selection of relevant studies, following strict inclusion and exclusion criteria, data was performed using STATA 12.0 software. Results. We retrieved 83 studies from database search using specific search terms. After multiple rounds of selection and elimination, 7 studies were finally identified as suitable to be included in our present meta-analysis, based on their relevance and data integrity. These 7 studies contained a combined total of 2,296 oral cancer patients and 3,647 healthy controls. Our findings demonstrated that +837 T>C (rs5275) polymorphism in COX-2 showed statistically significant differences in gene frequencies in case and control groups in allele model and dominant model. Similar results were obtained with COX-2 gene polymorphism −765G>C (rs20417). On the other hand, 1195A>G (rs689466) polymorphism in COX-2 did not confer susceptibility to oral cancers. Conclusion. Based on our results, COX-2 gene polymorphisms, +837 T>C (rs5275) and −765G>C (rs20417), showed clear links with oral cancer susceptibility, and the 1195A>G (rs689466) polymorphism did not show such a correlation.

1. Introduction

Oral cancer is the eighth most common head and neck cancer worldwide with high morbidity and mortality, and an estimated 27,450 new cases and 5,490 deaths were reported in the United States in 2013 [1]. In recent years, increasing incidence of oral cancers, especially in younger age groups, has posed a serious threat to public health [2]. In most countries, oral cancer is more frequent in men than women because of the more prevalent risky habits in men such as alcohol consumption, cigarette smoking, and betel quid chewing [3, 4]. Oral cancers are aggressive and frequently invade as well as metastasize to distant organs, thus making them difficult to cure [5]. The etiology of oral cancer is multifactorial and includes genetic components, environmental components, viral infections, and social and behavioral factors [6]. Individual variations in susceptibility to tobacco-related oral squamous cell carcinoma have been attributed to complex interactions between genetic and environmental factors [7], but the underlying mechanisms appear to converge on inflammation related pathways. Inflammation is closely related to altered gene expression of oncogenes and tumor suppressor genes and is a major factor in promoting neoplastic transformation [8]. Previous studies have established a connection between oral cancers and genetic polymorphisms in cyclooxygenase (COX), an enzyme that promotes the rate-limiting in the formation of inflammatory prostaglandins [2, 9].

COX-2, also named prostaglandin-endoperoxide synthase (PTGS), is a key enzyme in the arachidonic acid pathway, initiating the synthesis of biologically important
prostanoids and eicosanoids [10]. Overexpression of COX-2 is observed in many cancers, especially in the upper aerodigestive tract cancers, such as oral cancer, gastric cancer, and esophageal cancer, and is associated with cell proliferation, inhibition of apoptosis, tumor invasion, and angiogenesis [11]. The human COX-2 gene is located on chromosome 1 locus of 1q25.2-q25.3 and is 8.0 kbp in size with 10 exons [12]. COX-2 gene polymorphisms affect the expression levels and enzymatic activity of COX-2 and therefore are intimately linked to inflammatory response and individual variations in the susceptibility to oral cancers [13–15]. Three single-nucleotide polymorphisms (SNPs) in the COX-2 gene, −1195 G > A (reference SNP ID, rs689466), +837 T > C (rs5275), and −765 G > C (rs20417) have received considerable attention for their close links to oral cancers, compared to the other SNPs of COX-2 gene [16]. The +837 T > C (rs5275) polymorphism creates an E2F binding site in the promoter to alter COX-2 expression, and the −765 G > C (rs20417) polymorphism is located in the 3’UTR and influences COX-2 mRNA stability and translation. Both polymorphisms are independently associated with several cancers and evidence shows that polymorphisms of COX-2 gene, in general, enhance cancer risk [14]. However, controversy exists about the exact role of COX-2 genetic polymorphisms in cancers, especially in different ethnic groups [7]. Therefore, we conducted this meta-analysis using data extracted from selected case-control studies to investigate the association of three prominent COX-2 gene polymorphisms with the risk of oral cancer.

2. Methods and Materials

2.1. Identification of Eligible Studies. To identify all relevant studies on COX-2 gene polymorphisms and susceptibility to oral cancers, we exhaustively searched PubMed, EBSCO, Ovid, Springerlink, Wiley, Web of Science, VIP, Wanfang, and China National Knowledge Infrastructure (CNKI) databases (last updated search in October, 2014), utilizing selected keywords related to oral Cancer, COX-2, and polymorphism genetic. The search terms applied in our literature search were as follows: “Mouth Neoplasms” or “Oral Cancer” or “Tongue Neoplasms” or “Gingival Neoplasms” or “Lip Neoplasms” or “Palatal Neoplasms” or “Salivary Gland Neoplasms” and “Cyclooxygenase 2” or “COX-2” and “Polymorphism, Genetic”. We also manually examined the bibliographies of relevant articles to identify additional studies.

2.2. Selection Criteria. The following criteria were applied for literature selection to be included in the present meta-analysis: (1) study types should be case-control studies; (2) the study topic should be related to COX-2 gene polymorphism and oral cancer susceptibility; (3) the outcome index involved the allele gene and frequencies of genotype in both case and control groups; (4) when the same author published articles using the same clinical data, study with the largest sample size or the newest publication was used; (5) only studies published in English and Chinese are included. The major exclusion criteria were as follows: (1) containing summary and abstracts only; (2) nonhuman studies; (3) duplicate publications or unpublished studies; (4) no sufficient information provided.

2.3. Data Extraction and Quality Assessment. The data were extracted from each included study by two independent investigators, and the following information was collected: surname and initials of the first author, year of submission, country, ethnicity, language, age, gender, sample size, genotyping methods, study design, Hardy-Weinberg equilibrium test (HWE), SNP, and gene. Disagreement on the inclusion of any study was resolved by consultation with a third investigator. The quality of included trials was assessed utilizing the critical appraisal skills program (CASP) for case-control Studies (http://www.casp-uk.net/). The CASP criteria are scored as follows: the focused issue is clearly addressed (CASP01); the research problem is eligible and the research design answers the research problem (CASP02); the cases were enrolled acceptably (CASP03); the controls were selected acceptably (CASP04); the measurement for exposure factors is precise to minimize bias (CASP05); the study controls other crucial confounding factors (CASP06); the research results are complete (CASP07); the research results are precise (CASP08); the research results are reliable (CASP09); the research results are applicable to the local population (CASP10); the research results fit with other available evidence (CASP11).

2.4. Statistical Analysis. All statistical tests for this meta-analysis were performed with STATA 12.0 (Stata Corporation, College Station, TX, USA). The relative risk (RR) and 95% confidence intervals (CI) were estimated by fixed effects model or random effects model to evaluate the correlation between COX-2 gene polymorphism and the risk of oral cancer. Z test was applied to estimate the significance of the overall effect size [17]. We used Cochrans Q-statistic (Pq < 0.05 was considered significant) and I² tests to quantify heterogeneity among studies [18]. When P < 0.05 or I² > 50% indicated heterogeneity random effects model was used; otherwise fixed effects model was employed. In order to reflect the influence of single studies on the results the sensitivity analysis was employed. In addition, potential publication bias was examined by using funnel plots as well as Egger’s linear regression test to ensure the reliability of results (P < 0.05 was considered significant) [19, 20].

3. Results

3.1. Study Characteristics. A total of 83 articles were retrieved through electronic database and manual searches. After rejecting 31 duplicate studies, 3 letters and reviews, 5 nonhuman studies, and 22 unrelated studies, the remaining studies were reviewed in full text for data integrity. This resulted in further elimination of 11 articles, along with 4 studies that lacked sufficient data (Figure 1). Eventually, 7 clinical studies [7, 21–26], containing a total of 2,296 oral cancer patients and 3,647 control subjects, met our inclusion criteria for quantitative data analysis. These studies were published between 2007 and 2012. Overall, 2 of the seven studies were
performed in Caucasians and 5 studies were in Asians (four Chinese and one Indian). Among the 7 included studies, 3 studies used TaqMan method and four studies used PCR-RFLP to detect SNPs, and the patient numbers ranged from 194–1200. Except for +837 T > C (rs5275) allele in the study of Mittal M, 2010 (P = 0.006), other genotype distributions were in accordance with HWE (P > 0.05). CASP scores and baseline characteristics for eligible studies are presented in Figure 2 and Table 1, respectively.

3.2. Meta-Analysis of Association between +837 T > C (rs5275) and the Susceptibility of Oral Cancer. Four studies reported the association between +837 T > C (rs5275) COX-2 gene polymorphism and the susceptibility to oral cancer. According to the heterogeneity test, the studies showed significant heterogeneity (allele model: I² = 52.7%, Pₕ = 0.096; dominant model: I² = 91.1%, Pₕ < 0.001). Our findings demonstrated that +837 T > C (rs5275) polymorphism in COX-2 elevates the susceptibility to oral cancer and there were significant statistical differences in gene frequencies between the case and control groups in both allele model and dominant model (allele model: RR = 0.87, 95% CI = 0.77–0.98, P = 0.021; dominant model: RR = 0.53, 95% CI = 0.40–0.72, P < 0.001) (Figure 3, Table 2).

3.3. Meta-Analysis of Association between −765 G > C (rs20417) and the Susceptibility of Oral Cancer. A total of four studies reported that the −765 G > C (rs20417) polymorphism in COX-2 related to the susceptibility to oral cancer. The result of the heterogeneity test indicated significant heterogeneity among various studies (allele model: I² = 83.6%, Pₕ < 0.001; dominant model: I² = 81.2%, Pₕ = 0.001). Our analysis suggested that the COX-2 gene polymorphism 765 G > C (rs20417) is correlated with the susceptibility of oral cancers. The gene frequencies of case group and control group, under allele model and dominant model, exhibited significant differences (allele model: RR = 0.66, 95% CI = 0.58–0.76, P < 0.001; dominant model: RR = 0.72, 95% CI = 0.64–0.82, P < 0.001) (Figure 3, Table 2).

3.4. Meta-Analysis of Association between 1195 A > G (rs689466) and the Susceptibility of Oral Cancer. Three studies reported that the 1195 A > G (rs689466) polymorphism in
COX-2 linked with susceptibility to oral cancer. No significant heterogeneity was detected; thus fixed effects model was adopted (allele model: $I^2 = 12.2\%, P_h = 0.320$; dominant model: $I^2 = 1.5\%, P_h = 0.362$). Our findings of meta-analysis showed that 1195 A $\rightarrow$ G (rs20417) variant alleles were associated with significantly increased risk of oral cancer, while the effects of 1195 A $\rightarrow$ G (rs689466) need further exploration. The guanine (G) to cytosine (C) conversion at position −765bp lies in the promoter region of COX-2 gene, and the −765 G $\rightarrow$ C polymorphism affects transcription activity and is the most extensivelystudied COX-2 polymorphism [11]. The −765 G $\rightarrow$ C test illustrated no presence of publication bias ($P > 0.05$), indicating highly reliable results (Figure 6).

4. Discussion

COX-2 is an inducible enzyme that catalyzes the conversion of arachidonic acid to prostaglandins, and the reaction products influence cell proliferation and are key mediators of inflammation [9]. Evidences suggest that COX-2 plays a key role in carcinogenesis by inhibiting apoptosis, promoting tumor growth, angiogenesis, invasion, and metastasis [16, 27–29]. Given the important roles of COX-2 in the etiology of oral cancers, genetic variations of COX-2 gene affect the susceptibility to cancer development [13]. In our meta-analysis, the COX-2 +837 T $\rightarrow$ C (rs5275) and −765 G $\rightarrow$ C (rs20417) variant alleles were associated with significantly increased risk of oral cancer, while the effects of 1195 A $\rightarrow$ G (rs689466) need further exploration. The guanine (G) to cytosine (C) conversion at position −765bp lies in the promoter region of COX-2 gene, and the −765 G $\rightarrow$ C polymorphism affects transcription activity and is the most extensivelystudied COX-2 polymorphism [11].
| Included study | rs5275 (M allele versus W allele) | RR (95% CI) | Weight (%) |
|----------------|---------------------------------|-------------|------------|
| Campa et al. (2007) | 0.90 (0.75, 1.08) | 38.50 |
| Pu et al. (2009) | 0.68 (0.54, 0.86) | 26.58 |
| Mittal et al. (2010) | 1.09 (0.79, 1.51) | 11.47 |
| Niu et al. (2012) | 0.92 (0.71, 1.20) | 23.45 |

Heterogeneity test ($I^2 = 52.7\%, P = 0.096$)

Z test ($Z = 2.31, P = 0.021$)

| Included study | rs5275 (WM + MM versus WW) | RR (95% CI) | Weight (%) |
|----------------|-----------------------------|-------------|------------|
| Campa et al. (2007) | 0.63 (0.54, 0.74) | 25.74 |
| Pu et al. (2009) | 0.61 (0.50, 0.75) | 24.70 |
| Mittal et al. (2010) | 0.62 (0.54, 0.72) | 25.93 |
| Niu et al. (2012) | 0.32 (0.25, 0.40) | 23.63 |

Heterogeneity test ($I^2 = 91.1\%, P < 0.001$)

Z test ($Z = 4.15, P < 0.001$)

| Included study | rs20417 (M allele versus W allele) | RR (95% CI) | Weight (%) |
|----------------|----------------------------------|-------------|------------|
| Chiang et al. (2008) | 1.24 (0.82, 1.87) | 9.22 |
| Lin et al. (2008) | 0.51 (0.42, 0.62) | 56.01 |
| Pu et al. (2009) | 0.72 (0.50, 1.03) | 14.71 |
| Mittal et al. (2010) | 0.80 (0.61, 1.06) | 20.07 |

Heterogeneity test ($I^2 = 83.6\%, P < 0.001$)

Z test ($Z = 5.88, P < 0.001$)

| Included study | rs20417 (WM + MM versus WW) | RR (95% CI) | Weight (%) |
|----------------|----------------------------|-------------|------------|
| Chiang et al. (2008) | 0.66 (0.58, 0.76) | 100.00 |
| Lin et al. (2008) | 0.57 (0.47, 0.68) | 52.76 |
| Pu et al. (2009) | 0.74 (0.52, 1.04) | 15.42 |
| Mittal et al. (2010) | 0.83 (0.66, 1.05) | 21.08 |

Heterogeneity test ($I^2 = 81.2\%, P = 0.001$)

Z test ($Z = 5.10, P < 0.001$)

Figure 3: Continued.
Included study RR (95% CI) Weight (%)
Chiang et al. (2008) 0.90 (0.82, 0.99) 69.97
Mittal et al. (2010) 1.06 (0.74, 1.52) 8.17
Niu et al. (2011) 1.03 (0.87, 1.22) 21.86
Heterogeneity test ($I^2 = 12.2\%$, $P = 0.320$) 0.94 (0.87, 1.02) 100.00

Chiang et al. (2008) 0.92 (0.85, 0.99) 68.63
Mittal et al. (2010) 1.15 (0.81, 1.63) 9.37
Niu et al. (2011) 0.97 (0.84, 1.13) 22.83
Heterogeneity test ($I^2 = 1.5\%$, $P = 0.362$) 0.95 (0.89, 1.02) 100.00

**Figure 3:** Forest analyses in present meta-analysis investigate the association between COX-2 polymorphism and susceptibility to oral cancer ((a) +837 T $>$ C (rs5275) in allele model; (b) +837 T $>$ C (rs5275) in dominant model; (c) −765 G $>$ C (rs20417) in allele model; (d) −765 G $>$ C (rs20417) in dominant model; (e) 1195 A $>$ G (rs689466) in allele model; (f) 1195 A $>$ G (rs689466) in dominant model).

C (rs20417) located at the transcription start site prevents Sp1 binding but creates a new E2 promoter factor (E2F) binding site, leading to high transcription activity, which may be the mechanism underlying the increased cancer risk associated with −765 G $>$ C (rs20417) polymorphism [30]. COX-2 promoter activity of −765C is reduced at 70% compared to −765G, and this change is associated with altered plasma levels of C-reactive protein, a marker for inflammation [23]. Furthermore, stability of COX-2 mRNA is influenced by 3′UTR elements, and the exon 10 +837 T $>$ C SNP is located in the 3′UTR and alters mRNA stability and translation efficiency to influence susceptibility to oral cancer [11, 14]. Thus, the two SNPs, +837 T $>$ C (rs5275) and −765 G $>$ C (rs20417), alter COX-2 protein levels by virtue of their effects on transcription and mRNA stability of COX-2 and modulate the degree and extent of inflammatory responses, contributing to individual variations in susceptibility to oral cancer [16]. Our conclusions are supported by previous observations that −765 G $>$ C and +837 T $>$ C polymorphisms are associated with high risk of oral cancer [10, 14].

Limitations of the present study should be acknowledged. First, the sample sizes in several of the incorporated studies were relatively small, which may reduce the strength of our conclusions. Second, all eligible studies were published in English and Chinese and indexed by the selected databases. It is possible that studies published in other languages or unpublished studies could be missed, which might bias the results. In addition, our result was on the basis of unadjusted estimates, while a more accurate analysis should be carried out if more detailed individual information was available, which would allow for an adjusted estimate by other causes such as age and sex.

In summary, our meta-analysis revealed a strong association between the −765 G $>$ C and +837 T $>$ C polymorphisms and the susceptibility to oral cancer. Therefore, COX-2 polymorphisms, −765 G $>$ C and +837 T $>$ C, are linked to increased risk to oral cancers. However, the I195 A $>$ G polymorphism has no influence on oral cancer risk and will need to be explored further. More studies involving gene-gene and gene-environment interactions should also be taken into consideration in future analyses, which should lead to better, more comprehensive understanding of the correlation of the COX-2 gene polymorphisms with the risk of oral cancers.

**Conflict of Interests**
The authors declared that no competing interests exist.
| SNP gene model                              | +837 T > C (rs5275) | −765 G > C (rs20417) | 1895 G > A (rs689466) |
|--------------------------------------------|----------------------|----------------------|----------------------|
| M allele versus W allele (allele model)    | RR 0.87, 95% CI 0.77–0.98, P 0.021 | RR 0.66, 95% CI 0.58–0.76, P <0.001 | RR 0.94, 95% CI 0.87–1.02, P 0.164 |
| WM + MM versus WW (dominant model)         | RR 0.53, 95% CI 0.40–0.72, P <0.001 | RR 0.72, 95% CI 0.64–0.82, P <0.001 | RR 0.95, 95% CI 0.89–1.02, P 0.186 |
| MM versus WW (homozygous model)            | RR 0.68, 95% CI 0.47–0.99, P 0.042 | RR 0.26, 95% CI 0.16–0.43, P <0.001 | RR 0.85, 95% CI 0.71–1.01, P 0.069 |
| MM versus WM (heterozygous model)          | RR 1.01, 95% CI 0.92–1.11, P 0.806 | RR 1.11, 95% CI 1.03–1.18, P 0.004 | RR 1.01, 95% CI 0.93–1.10, P 0.734 |
| MM versus WW + WM (recessive model)        | RR 0.72, 95% CI 0.49–1.06, P 0.093 | RR 0.32, 95% CI 0.19–0.54, P <0.001 | RR 0.91, 95% CI 0.73–1.12, P 0.363 |

RR: relative risk; 95% CI: 95% confidential intervals.

Table 2: Comparisons of genotype and allele frequencies between the case and the control groups for the relationship between functional COX-2 gene polymorphisms and susceptibility to oral cancer.
Figure 4: Sensitivity analysis in present meta-analysis investigates the association between COX-2 polymorphisms and susceptibility to oral cancer ((a) +837 T > C (rs5275) in allele model; (b) +837 T > C (rs5275) in dominant model; (c) −765 G > C (rs20417) in allele model; (d) −765 G > C (rs20417) in dominant model; (e) 1195 A > G (rs689466) in allele model; (f) 1195 A > G (rs689466) in dominant model).
Figure 5: Metaregression analysis in present meta-analysis investigates association between COX-2 polymorphisms and susceptibility to oral cancer ((a) +837 T > C (rs5275) in allele model; (b) +837 T > C (rs5275) in dominant model; (c) −765 G > C (rs20417) in allele model; (d) −765 G > C (rs20417) in dominant model; (e) 1195 A > G (rs689466) in allele model; (f) 1195 A > G (rs689466) in dominant model).
Figure 6: Funnel plot of publication in present meta-analysis investigates the association between COX-2 polymorphisms and susceptibility to oral cancer ((a) +837 T > C (rs5275) in allele model; (b) +837 T > C (rs5275) in dominant model; (c) −765 G > C (rs20417) in allele model; (d) −765 G > C (rs20417) in dominant model; (e) 1195 A > G (rs689466) in allele model; (f) 1195 A > G (rs689466) in dominant model).
Table 3: Meta-regression analyses on SNP, detecting method, year, country, ethnicity and sample size for exploring potential source of heterogeneity between functional COX-2 gene polymorphisms and susceptibility to oral cancer.

| Heterogeneity factors | Coefficient | SE  | t       | P (adjusted) | 95% CI        |
|-----------------------|-------------|-----|---------|-------------|---------------|
| SNP                   | −0.071      | 0.082| −0.86   | 0.805       | −0.299–0.158  |
| Detecting method      | 1.964       | 0.812| 2.42    | 0.181       | −0.291–4.22   |
| Year                  | 0.301       | 0.130| 2.32    | 0.206       | −0.059–0.661  |
| Country               | 0.124       | 0.098| 1.27    | 0.588       | −0.148–0.395  |
| Ethnicity             | −2.103      | 0.962| −2.19   | 0.232       | −4.774–0.568  |
| Sample size           | 0.002       | 0.001| 2.21    | 0.230       | −0.001–0.004  |

Note: SE: standard error; LL: lower limit; UL: upper limit; SNP: single-nucleotide polymorphism.

Acknowledgments

The authors would like to appreciate the reviewers for their helpful comments on this meta-analysis.

References

[1] C. Fuller, R. Camilon, S. Nguyen, J. Jennings, T. Day, and M. B. Gillespie, "Adjunctive diagnostic techniques for oral lesions of a mammalian potential: systematic review with meta-analysis," *Head & Neck*, 2014.

[2] Y. X. Yan, W. Z. Li, Y. Q. Huang, and W. X. Liao, "The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function," *Prostaglandins and Other Lipid Mediators*, vol. 97, no. 1-2, pp. 29-35, 2012.

[3] S. Warnakulasuriya, "Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival," *Oral Oncology*, vol. 46, no. 6, pp. 407-410, 2010.

[4] K.-T. Yu, C. Ge, X.-F. Xu, J.-C. Zou, X. Zou, and S. Zhen, "CYP1A1 polymorphism interactions with smoking status in oral cancer risk: evidence from epidemiological studies," *Tumor Biology*, vol. 35, no. 11, pp. 11183–11191, 2014.

[5] R. Mishra, "Glycogen synthase kinase 3 beta: can it be a target for oral cancer," *Molecular Cancer*, vol. 9, article 144, 2010.

[6] R. Lu, H. Dan, R. Wu et al., "Lycopene: features and potential significance in the oral cancer and precancerous lesions," *Journal of Oral Pathology and Medicine*, vol. 40, no. 5, pp. 361–368, 2011.

[7] M. Mittal, V. Kapoor, B. K. Mohanti, and S. N. Das, "Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians," *Oral Oncology*, vol. 46, no. 8, pp. 622–626, 2010.

[8] A. J. Schetter, N. H. H. Heegaard, and C. C. Harris, "Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways," *Carcinogenesis*, vol. 31, no. 1, pp. 37–49, 2010.

[9] H. Zhang, Y. Xu, Z. Zhang, R. Liu, and B. Ma, "Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis," *BMC Immunology*, vol. 13, article 14, 2012.

[10] R. Talar-Wojnarowska, A. Gasiorowska, M. Olakowski et al., "Role of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesis," *World Journal of Gastroenterology*, vol. 17, no. 36, pp. 4113–4117, 2011.

[11] Y. Niu, H. Yuan, M. Shen, H. Li, Y. Hu, and N. Chen, "Association between Cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk," *Journal of Craniofacial Surgery*, vol. 25, no. 2, pp. 333–337, 2014.

[12] T. Kosaka, A. Miyata, H. Ihara et al., "Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2," *European Journal of Biochemistry*, vol. 221, no. 3, pp. 889–897, 1994.

[13] F. Zhao, Y. Cao, H. Zhu, M. Huang, C. Yi, and Y. Huang, "The -765G>C polymorphism in the cyclooxygenase-2 gene and digestive system cancer: a meta-analysis," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 19, pp. 8301–8310, 2014.

[14] W. Zhu, B.-B. Wei, X. Shan, and P. Liu, "-765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies," *Molecular Biology Reports*, vol. 37, no. 1, pp. 277–288, 2010.

[15] L.-J. Chen, W. Xu, Y. Taoaka et al., "Cyclooxygenase 2 1195G>A polymorphism is associated with chronic obstructive pulmonary disease in Japanese and Chinese patients," *Chinese Medical Journal*, vol. 126, no. 12, pp. 2215–2221, 2013.

[16] J. Dong, J. Dai, M. Zhang, Z. Hu, and H. Shen, "Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis," *Journal of Gastroenterology and Hepatology*, vol. 25, no. 6, pp. 1042–1050, 2010.

[17] H. Chen, A. K. Manning, and J. Dupuis, "A method of moments estimator for random effect multivariate meta-analysis," *Biometrics*, vol. 68, no. 4, pp. 1278–1284, 2012.

[18] E. Zintzaras and J. P. A. Ioannidis, "HEGESMA: genome search meta-analysis and heterogeneity testing," *Bioinformatics*, vol. 21, no. 18, pp. 3672–3673, 2005.

[19] F. Song and S. Gilbody, "Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis," *British Medical Journal*, vol. 316, no. 7129, p. 471, 1998.

[20] J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, "Comparison of two methods to detect publication bias in meta-analysis," *The Journal of the American Medical Association*, vol. 295, no. 6, pp. 676–680, 2006.

[21] D. Campa, M. Hashibe, D. Zaridze et al., "Association of common polymorphisms in inflammatory genes with risk of developing cancers of the upper aerodigestive tract," *Cancer Causes and Control*, vol. 18, no. 4, pp. 449–455, 2007.

[22] S.-L. Chiang, P.-H. Chen, C.-H. Lee et al., "Up-regulation of inflammatory signalings by areca nut extract and role of Cyclooxygenase-2 -1195G>A polymorphism reveal risk of oral cancer," *Cancer Research*, vol. 68, no. 20, pp. 8489–8498, 2008.
[23] Y.-C. Lin, H.-I. Huang, L.-H. Wang et al., “Polymorphisms of COX-2 -765G > C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population,” Oral Oncology, vol. 44, no. 8, pp. 798–804, 2008.

[24] Y. M. Niu, N. Chen, Y. Y. Hu et al., “A study of the association of COX-2 gene promoter region −1195 A>G polymorphism and oral squamous cell carcinoma,” Journal of Clinical Stomatology, vol. 27, no. 11, pp. 646–648, 2011.

[25] Y. M. Niu, M. Shen, N. Chen et al., “A study of the association between COX-2 gene 8437T>C polymorphism and oral squamous cell carcinoma,” Journal of Clinical Stomatology, no. 11, pp. 647–649, 2012.

[26] X. Pu, S. M. Lippman, H. Yang, J. J. Lee, and X. Wu, “Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions,” Cancer, vol. 115, no. 7, pp. 1498–1506, 2009.

[27] K.-S. Gu and Y. Chen, “Mechanism of P-glycoprotein expression in the SGC7901 human gastric adenocarcinoma cell line induced by cyclooxygenase-2,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2379–2383, 2012.

[28] F. Huang, C. Lin, Y.-H. Shi, and G. Kuerban, “MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in hela cervical carcinoma cells,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 10, pp. 5915–5920, 2013.

[29] N. Saad, N. M. Esa, and H. Ithnin, “Suppression of β-catenin and cyclooxygenase-2 expression and cell proliferation in azoxymethane-induced colonic cancer in rats by rice bran phytic acid (PA),” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 5, pp. 3093–3099, 2013.

[30] X.-F. Wang, M.-Z. Huang, X.-W. Zhang, R.-X. Hua, and W.-J. Guo, “COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis,” PLoS ONE, vol. 8, no. 9, Article ID e73213, 2013.